News : licensagreement

Moberg Derma AB (publ) has entered into distribution agreements with AG Farma S.A. in Spain and HairXpertise Ltd in UK for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. Under the agreements, the distributors are granted exclusive rights to market and sell Emtrix®.
”The agreements follow on a positive response in the Nordic market. Already...

Moberg Derma AB, Sweden, today announced a commercial agreement with Perrigo Company that covers distribution in Israel for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in...

Moberg Derma AB, Sweden and Medical Futures Inc, Canada (“MFI”), today announced a commercial license agreement. The license covers distribution in Canada for Moberg Derma’s novel topical nail product – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while MFI will be responsible for promotion in the...

Moberg Derma AB and MedPharm Ltd today announce a license and distribution agreement for the development, marketing and sales of new dermatology products that will combine Moberg Derma’s Kaprolac® platform with MedPharm’s MedSpray™ technology. According to the agreement, MedPharm will be eligible for royalty payments.
Moberg Derma obtains the exclusive rights to worldwide manufacturing, distribution and sales...